Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD 19/03/2014

Description

A phase 4, multi-centre, three-arm, randomised, open-label [SF1] clinical trial lasting 12 months, to evaluate the efficacy and safety of two treatment systems: the bimonthly or individualised flexible PRN “treat-and-extend” regimen; versus a PRN regimen of intravitreal injections of Ranibizumab 0.5 mg in keeping with stabilisation criteria based on monthly controls [SF2] in antiretroviral-naive patients with choroidal neovascularization secondary to age-related macular degeneration. An IN-EyE study.

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155

Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

Author

Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal